Abstract
During the past decade, the Pediatric Oncology Group (POG) clinical trials for childhood acute myelogenous leukemia (AML) have focused on the early phases of treatment since the median time to relapse tends to occur within the first six to nine months after diagnosis. The POG protocols have asked both remission induction and postremission questions with an emphasis on dose intensity of cytosine arabinoside (ara-C) and ’the use of “non cross-resistant pairs of drugs” [1,2]. The most recent POG protocol (AML 8821) asked a postremission question comparing autologous bone marrow transplantation to six months of multi-agent chemotherapy that included high dose ara-C. The long term results of the POG protocols 8101 and 8498 and the preliminary results from POG 8821 are reported in this manuscript.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
